JP2018500019A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500019A5 JP2018500019A5 JP2017531662A JP2017531662A JP2018500019A5 JP 2018500019 A5 JP2018500019 A5 JP 2018500019A5 JP 2017531662 A JP2017531662 A JP 2017531662A JP 2017531662 A JP2017531662 A JP 2017531662A JP 2018500019 A5 JP2018500019 A5 JP 2018500019A5
- Authority
- JP
- Japan
- Prior art keywords
- region
- item
- nucleic acid
- multimerization
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 356
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 325
- 229920001184 polypeptide Polymers 0.000 claims description 323
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 323
- 102000039446 nucleic acids Human genes 0.000 claims description 225
- 108020004707 nucleic acids Proteins 0.000 claims description 225
- 150000007523 nucleic acids Chemical class 0.000 claims description 225
- 108091033319 polynucleotide Proteins 0.000 claims description 167
- 102000040430 polynucleotide Human genes 0.000 claims description 167
- 239000002157 polynucleotide Substances 0.000 claims description 167
- 239000003446 ligand Substances 0.000 claims description 149
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 claims description 63
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 claims description 63
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 claims description 48
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 claims description 48
- 150000001413 amino acids Chemical group 0.000 claims description 46
- 101150013553 CD40 gene Proteins 0.000 claims description 42
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 42
- 239000000427 antigen Substances 0.000 claims description 38
- 108091007433 antigens Proteins 0.000 claims description 38
- 102000036639 antigens Human genes 0.000 claims description 38
- 230000000861 pro-apoptotic effect Effects 0.000 claims description 34
- 229960002930 sirolimus Drugs 0.000 claims description 34
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 30
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 30
- 102000004039 Caspase-9 Human genes 0.000 claims description 28
- 108090000566 Caspase-9 Proteins 0.000 claims description 28
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 22
- 230000001086 cytosolic effect Effects 0.000 claims description 22
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 17
- 108091008874 T cell receptors Proteins 0.000 claims description 12
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 12
- -1 Muc16 Proteins 0.000 claims description 7
- 101150029707 ERBB2 gene Proteins 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 6
- 235000001014 amino acid Nutrition 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 5
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims description 5
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 claims description 5
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 5
- 210000000822 natural killer cell Anatomy 0.000 claims description 5
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 5
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 4
- 108010058905 CD44v6 antigen Proteins 0.000 claims description 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 4
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 4
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 4
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 4
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- 102000003735 Mesothelin Human genes 0.000 claims description 4
- 108090000015 Mesothelin Proteins 0.000 claims description 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 description 178
- 102000011727 Caspases Human genes 0.000 description 31
- 108010076667 Caspases Proteins 0.000 description 31
- 239000000203 mixture Substances 0.000 description 27
- 239000000178 monomer Substances 0.000 description 18
- 239000013598 vector Substances 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 11
- 239000012634 fragment Substances 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 230000001640 apoptogenic effect Effects 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 206010010099 Combined immunodeficiency Diseases 0.000 description 6
- 238000002659 cell therapy Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 206010010356 Congenital anomaly Diseases 0.000 description 4
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 4
- 102100038713 Death domain-containing protein CRADD Human genes 0.000 description 4
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 description 4
- 208000032672 Histiocytosis haematophagic Diseases 0.000 description 4
- 101000957914 Homo sapiens Death domain-containing protein CRADD Proteins 0.000 description 4
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- 208000029462 Immunodeficiency disease Diseases 0.000 description 4
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 210000001671 embryonic stem cell Anatomy 0.000 description 4
- 208000014752 hemophagocytic syndrome Diseases 0.000 description 4
- 230000007813 immunodeficiency Effects 0.000 description 4
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 230000006044 T cell activation Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000007056 sickle cell anemia Diseases 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 102100033051 40S ribosomal protein S19 Human genes 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- 102100034524 Apoptotic protease-activating factor 1 Human genes 0.000 description 2
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 2
- 208000033932 Blackfan-Diamond anemia Diseases 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 2
- 208000018240 Bone Marrow Failure disease Diseases 0.000 description 2
- 206010065553 Bone marrow failure Diseases 0.000 description 2
- 201000007155 CD40 ligand deficiency Diseases 0.000 description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 102000004018 Caspase 6 Human genes 0.000 description 2
- 108090000425 Caspase 6 Proteins 0.000 description 2
- 108090000567 Caspase 7 Proteins 0.000 description 2
- 102100035904 Caspase-1 Human genes 0.000 description 2
- 108090000426 Caspase-1 Proteins 0.000 description 2
- 102000004068 Caspase-10 Human genes 0.000 description 2
- 108090000572 Caspase-10 Proteins 0.000 description 2
- 102000004066 Caspase-12 Human genes 0.000 description 2
- 108090000570 Caspase-12 Proteins 0.000 description 2
- 102000004958 Caspase-14 Human genes 0.000 description 2
- 108090001132 Caspase-14 Proteins 0.000 description 2
- 102000004046 Caspase-2 Human genes 0.000 description 2
- 108090000552 Caspase-2 Proteins 0.000 description 2
- 102100029855 Caspase-3 Human genes 0.000 description 2
- 102100025597 Caspase-4 Human genes 0.000 description 2
- 101710090338 Caspase-4 Proteins 0.000 description 2
- 102100038916 Caspase-5 Human genes 0.000 description 2
- 101710090333 Caspase-5 Proteins 0.000 description 2
- 102100038902 Caspase-7 Human genes 0.000 description 2
- 102100026548 Caspase-8 Human genes 0.000 description 2
- 108090000538 Caspase-8 Proteins 0.000 description 2
- 201000003874 Common Variable Immunodeficiency Diseases 0.000 description 2
- 208000025212 Constitutional neutropenia Diseases 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- 208000017701 Endocrine disease Diseases 0.000 description 2
- 102100026693 FAS-associated death domain protein Human genes 0.000 description 2
- 201000004939 Fanconi anemia Diseases 0.000 description 2
- 208000000259 GATA2 Deficiency Diseases 0.000 description 2
- 208000022140 GATA2 deficiency with susceptibility to MDS/AML Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 2
- 101000924629 Homo sapiens Apoptotic protease-activating factor 1 Proteins 0.000 description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 2
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 2
- 101001089266 Homo sapiens Receptor-interacting serine/threonine-protein kinase 3 Proteins 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 102000009438 IgE Receptors Human genes 0.000 description 2
- 108010073816 IgE Receptors Proteins 0.000 description 2
- 206010052210 Infantile genetic agranulocytosis Diseases 0.000 description 2
- 102000004551 Interleukin-10 Receptors Human genes 0.000 description 2
- 108010017550 Interleukin-10 Receptors Proteins 0.000 description 2
- 208000001126 Keratosis Diseases 0.000 description 2
- 201000001779 Leukocyte adhesion deficiency Diseases 0.000 description 2
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 2
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 101000933115 Mus musculus Caspase-4 Proteins 0.000 description 2
- 108010001657 NK Cell Lectin-Like Receptor Subfamily K Proteins 0.000 description 2
- 102000000812 NK Cell Lectin-Like Receptor Subfamily K Human genes 0.000 description 2
- 108060006580 PRAME Proteins 0.000 description 2
- 102000036673 PRAME Human genes 0.000 description 2
- 208000031951 Primary immunodeficiency Diseases 0.000 description 2
- 102100033729 Receptor-interacting serine/threonine-protein kinase 3 Human genes 0.000 description 2
- 208000010346 Sphingolipidoses Diseases 0.000 description 2
- 201000001307 Sphingolipidosis Diseases 0.000 description 2
- 201000001322 T cell deficiency Diseases 0.000 description 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 2
- 208000002903 Thalassemia Diseases 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 102000055574 bcl-2 Homologous Antagonist-Killer Human genes 0.000 description 2
- 102000055102 bcl-2-Associated X Human genes 0.000 description 2
- 208000015322 bone marrow disease Diseases 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 108010018550 caspase 13 Proteins 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000030172 endocrine system disease Diseases 0.000 description 2
- 208000037902 enteropathy Diseases 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 230000003258 hemophagocytic effect Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 208000014165 immunodeficiency 21 Diseases 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 235000020938 metabolic status Nutrition 0.000 description 2
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 2
- 210000000581 natural killer T-cell Anatomy 0.000 description 2
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 208000002865 osteopetrosis Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 210000004986 primary T-cell Anatomy 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 201000004283 Shwachman-Diamond syndrome Diseases 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462092149P | 2014-12-15 | 2014-12-15 | |
| US62/092,149 | 2014-12-15 | ||
| US201562148386P | 2015-04-16 | 2015-04-16 | |
| US62/148,386 | 2015-04-16 | ||
| PCT/US2015/065646 WO2016100241A2 (en) | 2014-12-15 | 2015-12-14 | Methods for controlled activation or elimination of therapeutic cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020104262A Division JP2020191870A (ja) | 2014-12-15 | 2020-06-17 | 治療用細胞のコントロールされた活性化または排除のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018500019A JP2018500019A (ja) | 2018-01-11 |
| JP2018500019A5 true JP2018500019A5 (cg-RX-API-DMAC7.html) | 2019-01-24 |
| JP6720176B2 JP6720176B2 (ja) | 2020-07-08 |
Family
ID=55135522
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017531662A Active JP6720176B2 (ja) | 2014-12-15 | 2015-12-14 | 治療用細胞のコントロールされた活性化または排除のための方法 |
| JP2020104262A Withdrawn JP2020191870A (ja) | 2014-12-15 | 2020-06-17 | 治療用細胞のコントロールされた活性化または排除のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020104262A Withdrawn JP2020191870A (ja) | 2014-12-15 | 2020-06-17 | 治療用細胞のコントロールされた活性化または排除のための方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20160175359A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3234145B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6720176B2 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2015362753A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2966241A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3234145T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2743232T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1245827B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016100241A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| WO2014100615A1 (en) | 2012-12-20 | 2014-06-26 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| JP6467406B2 (ja) | 2013-06-05 | 2019-02-13 | ベリカム ファーマシューティカルズ， インコーポレイテッド | カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法 |
| CA2959168A1 (en) | 2014-09-02 | 2016-03-10 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides |
| GB201503133D0 (en) | 2015-02-24 | 2015-04-08 | Ucl Business Plc And Syncona Partners Llp | Chimeric protein |
| KR20180053744A (ko) | 2015-09-23 | 2018-05-23 | 사이토이뮨 테라퓨틱스 엘엘씨 | 면역 요법을 위한 flt3 유도된 car 세포 |
| WO2017069958A2 (en) | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
| WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
| CA3005878A1 (en) | 2015-11-19 | 2017-05-26 | The Brigham And Women's Hospital, Inc. | Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| WO2018049025A2 (en) | 2016-09-07 | 2018-03-15 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses |
| WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| WO2018089386A1 (en) | 2016-11-11 | 2018-05-17 | The Broad Institute, Inc. | Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action |
| WO2018102761A1 (en) * | 2016-12-02 | 2018-06-07 | City Of Hope | Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors |
| WO2018129332A1 (en) * | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists |
| EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
| CN110582288B (zh) | 2017-02-28 | 2024-09-20 | 恩多塞特公司 | 用于car t细胞疗法的组合物和方法 |
| US11963966B2 (en) | 2017-03-31 | 2024-04-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
| EP3606518A4 (en) | 2017-04-01 | 2021-04-07 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER |
| US20200071773A1 (en) | 2017-04-12 | 2020-03-05 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
| EP3621988A1 (en) | 2017-05-09 | 2020-03-18 | Bellicum Pharmaceuticals, Inc. | Methods to augment or alter signal transduction |
| EP3622092A4 (en) | 2017-05-11 | 2021-06-23 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF |
| EP3638218A4 (en) | 2017-06-14 | 2021-06-09 | The Broad Institute, Inc. | COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH |
| US12178830B2 (en) | 2017-06-30 | 2024-12-31 | Memorial Sloan Kettering Cancer Center | Compositions and methods for adoptive cell therapy for cancer |
| WO2019006468A1 (en) | 2017-06-30 | 2019-01-03 | Memorial Sloan Kettering Cancer Center | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY |
| WO2019006467A1 (en) * | 2017-06-30 | 2019-01-03 | Memorial Sloan Kettering Cancer Center | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY |
| WO2019006465A1 (en) | 2017-06-30 | 2019-01-03 | Memorial Sloan Kettering Cancer Center | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY AGAINST CANCER |
| WO2019014581A1 (en) | 2017-07-14 | 2019-01-17 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE |
| CN107557337B (zh) * | 2017-09-15 | 2020-06-26 | 山东兴瑞生物科技有限公司 | 一种抗ror1安全型嵌合抗原受体修饰的免疫细胞及其应用 |
| EP3695408A4 (en) | 2017-10-02 | 2021-12-15 | The Broad Institute, Inc. | PROCEDURES AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANT GENE SIGNATURE IN CANCER |
| WO2019084055A1 (en) | 2017-10-23 | 2019-05-02 | Massachusetts Institute Of Technology | CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS |
| US12171783B2 (en) | 2017-11-13 | 2024-12-24 | The Broad Institute, Inc. | Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas |
| WO2019094983A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
| EP3720479A2 (en) | 2017-12-08 | 2020-10-14 | Bellicum Pharmaceuticals, Inc. | Methods for enhancing and maintaining car-t cell efficacy |
| EP3723787A4 (en) | 2017-12-14 | 2021-09-01 | Bluebird Bio, Inc. | DARIC INTERLEUKIN RECEPTORS |
| RU2020122708A (ru) * | 2017-12-14 | 2022-01-14 | 2севэнти био, Инк. | Рецепторы nkg2d daric |
| EP3728189A1 (en) | 2017-12-20 | 2020-10-28 | Bellicum Pharmaceuticals, Inc. | Multimeric piperidine derivatives |
| US11994512B2 (en) | 2018-01-04 | 2024-05-28 | Massachusetts Institute Of Technology | Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity |
| CN112055595B (zh) | 2018-01-22 | 2024-12-17 | 恩多塞特公司 | Car t细胞的使用方法 |
| US20210040469A1 (en) * | 2018-01-25 | 2021-02-11 | University Of Washington | Engineered cell death-inducing enzymes and methods of use |
| CA3090089A1 (en) | 2018-02-06 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための配列決定法 |
| EP4495246A3 (en) | 2018-03-01 | 2025-03-26 | University of Kansas | Techniques for generating cell-based therapeutics using recombinant t cell receptor genes |
| US12163169B2 (en) | 2018-03-02 | 2024-12-10 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| WO2019202323A1 (en) | 2018-04-18 | 2019-10-24 | Ucl Business Plc | Method for enhancing the suppressive properties of treg cells |
| US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
| US12410231B2 (en) | 2018-05-07 | 2025-09-09 | Board Of Regents Of The University Of Texas System | Natural killer cell products and methods |
| WO2019222579A1 (en) * | 2018-05-17 | 2019-11-21 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors with myd88 and cd40 costimulatory domains |
| WO2019232542A2 (en) | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
| US12036240B2 (en) | 2018-06-14 | 2024-07-16 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
| US20210379057A1 (en) | 2018-10-16 | 2021-12-09 | Massachusetts Institute Of Technology | Nutlin-3a for use in treating a mycobacterium tuberculosis infection |
| WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
| KR20210136041A (ko) | 2019-03-01 | 2021-11-16 | 알로젠 테라퓨틱스 인코포레이티드 | 구성적으로 활성인 키메라 사이토카인 수용체 |
| CA3129862A1 (en) | 2019-03-01 | 2020-09-10 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a pd-1 ectodomain |
| US20220154282A1 (en) | 2019-03-12 | 2022-05-19 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
| US20220142948A1 (en) | 2019-03-18 | 2022-05-12 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
| US20220235340A1 (en) | 2019-05-20 | 2022-07-28 | The Broad Institute, Inc. | Novel crispr-cas systems and uses thereof |
| WO2020243371A1 (en) | 2019-05-28 | 2020-12-03 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
| WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
| US12421557B2 (en) | 2019-08-16 | 2025-09-23 | The Broad Institute, Inc. | Methods for predicting outcomes and treating colorectal cancer using a cell atlas |
| WO2021041922A1 (en) | 2019-08-30 | 2021-03-04 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
| EP4037705A4 (en) * | 2019-09-30 | 2024-02-21 | Candel Therapeutics, Inc. | Combination gmci and atri cancer treatment |
| US12297426B2 (en) | 2019-10-01 | 2025-05-13 | The Broad Institute, Inc. | DNA damage response signature guided rational design of CRISPR-based systems and therapies |
| US12394502B2 (en) | 2019-10-02 | 2025-08-19 | The General Hospital Corporation | Method for predicting HLA-binding peptides using protein structural features |
| US12195725B2 (en) | 2019-10-03 | 2025-01-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity |
| US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
| US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
| US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
| US20240156864A1 (en) * | 2019-10-31 | 2024-05-16 | The University Of North Carolina At Chapel Hill | Methods and compositions for chimeric antigen receptor targeting cancer cells |
| US12165747B2 (en) | 2020-01-23 | 2024-12-10 | The Broad Institute, Inc. | Molecular spatial mapping of metastatic tumor microenvironment |
| PE20221757A1 (es) | 2020-02-24 | 2022-11-11 | Allogene Therapeutics Inc | Celulas t con car de bcma con actividades mejoradas |
| CA3175392A1 (en) | 2020-04-17 | 2021-10-21 | Michael A. Caligiuri | Flt3-targeted chimeric antigen receptor modified cells for treatment of flt3-positive malignancies |
| CN112156181A (zh) * | 2020-09-29 | 2021-01-01 | 广州恩宝生物医药科技有限公司 | 一种腺病毒四价疫苗 |
| WO2024011250A1 (en) | 2022-07-08 | 2024-01-11 | Viromissile, Inc. | Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof |
| WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
| WO2024124044A1 (en) | 2022-12-07 | 2024-06-13 | The Brigham And Women’S Hospital, Inc. | Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression |
| WO2024145622A1 (en) * | 2022-12-29 | 2024-07-04 | Kelonia Therapeutics, Inc. | Recombinant retroviruses, compositions, and methods of use |
| WO2024145605A1 (en) * | 2022-12-29 | 2024-07-04 | Kelonia Therapeutics, Inc. | Recombinant retroviruses, compositions, and methods of use |
| WO2025059533A1 (en) | 2023-09-13 | 2025-03-20 | The Broad Institute, Inc. | Crispr enzymes and systems |
| WO2025097055A2 (en) | 2023-11-02 | 2025-05-08 | The Broad Institute, Inc. | Compositions and methods of use of t cells in immunotherapy |
| WO2025117544A1 (en) | 2023-11-29 | 2025-06-05 | The Broad Institute, Inc. | Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0273085A1 (en) | 1986-12-29 | 1988-07-06 | IntraCel Corporation | A method for internalizing nucleic acids into eukaryotic cells |
| US5550318A (en) | 1990-04-17 | 1996-08-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
| US5484956A (en) | 1990-01-22 | 1996-01-16 | Dekalb Genetics Corporation | Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin |
| US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
| US5610042A (en) | 1991-10-07 | 1997-03-11 | Ciba-Geigy Corporation | Methods for stable transformation of wheat |
| DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| GB9222888D0 (en) | 1992-10-30 | 1992-12-16 | British Tech Group | Tomography |
| FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| AU714904C (en) * | 1995-06-07 | 2002-08-08 | Ariad Pharmaceuticals, Inc. | Rapamcycin-based regulation of biological events |
| US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
| ES2543084T3 (es) | 2003-02-18 | 2015-08-14 | Baylor College Of Medicine | Activación inducida en células dendríticas |
| US20100203067A1 (en) * | 2008-09-22 | 2010-08-12 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters |
| WO2011130566A2 (en) * | 2010-04-16 | 2011-10-20 | Bellicum Pharmaceuticals, Inc. | Method for treating solid tumors |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| EP2667196A1 (en) * | 2012-05-26 | 2013-11-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Bioorthogonal chemical inducers of reversible dimerization for control of protein interactions in cells |
| PT3300745T (pt) * | 2013-02-15 | 2019-11-27 | Univ California | Recetor de antigénio quimérico e métodos de utilização do mesmo |
| US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| US9944690B2 (en) * | 2013-03-14 | 2018-04-17 | Bellicum Pharmaceuticals, Inc. | Methods for controlling T cell proliferation |
| US20160160189A1 (en) * | 2013-05-01 | 2016-06-09 | St. Jude Children's Research Hospital | Truncated Constructs of RIPK3 and Related Uses |
| JP6467406B2 (ja) * | 2013-06-05 | 2019-02-13 | ベリカム ファーマシューティカルズ， インコーポレイテッド | カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法 |
| CA2937750A1 (en) * | 2014-02-14 | 2015-08-20 | Bellicum Pharmaceuticals, Inc. | Methods for activating t cells using an inducible chimeric polypeptide |
| US20170274014A1 (en) * | 2014-07-21 | 2017-09-28 | Jennifer Brogdon | Combinations of low, immune enhancing, doses of mtor inhibitors and cars |
| CA2959168A1 (en) * | 2014-09-02 | 2016-03-10 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides |
-
2015
- 2015-12-14 WO PCT/US2015/065646 patent/WO2016100241A2/en not_active Ceased
- 2015-12-14 JP JP2017531662A patent/JP6720176B2/ja active Active
- 2015-12-14 DK DK15823866.7T patent/DK3234145T3/da active
- 2015-12-14 EP EP15823866.7A patent/EP3234145B1/en active Active
- 2015-12-14 HK HK18105134.6A patent/HK1245827B/en not_active IP Right Cessation
- 2015-12-14 EP EP19178129.3A patent/EP3608408A1/en not_active Withdrawn
- 2015-12-14 AU AU2015362753A patent/AU2015362753A1/en not_active Abandoned
- 2015-12-14 ES ES15823866T patent/ES2743232T3/es active Active
- 2015-12-14 US US14/968,853 patent/US20160175359A1/en not_active Abandoned
- 2015-12-14 CA CA2966241A patent/CA2966241A1/en active Pending
-
2020
- 2020-06-17 JP JP2020104262A patent/JP2020191870A/ja not_active Withdrawn
-
2021
- 2021-06-21 US US17/353,587 patent/US20220152100A1/en active Pending
- 2021-09-08 AU AU2021229189A patent/AU2021229189A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018500019A5 (cg-RX-API-DMAC7.html) | ||
| JP2018501786A5 (cg-RX-API-DMAC7.html) | ||
| JP6584466B2 (ja) | 養子移入ｔリンパ球における副刺激リガンドの構成性発現 | |
| JP6997620B2 (ja) | Ｂ細胞成熟抗原を標的化するキメラ抗原受容体およびその使用 | |
| JP2024073636A (ja) | Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用 | |
| JP2021513347A (ja) | 非ｈｌａ制限ｔ細胞受容体およびその使用 | |
| JP2019506143A5 (cg-RX-API-DMAC7.html) | ||
| CA2969384A1 (en) | Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain | |
| CN112458057A (zh) | 用于免疫疗法的组合物和方法 | |
| EP3833682B1 (en) | Suicide module compositions and methods | |
| KR20140135715A (ko) | 항종양 활성 및 ｃａｒ 지속을 증진시키기 위한 ｉｃｏｓ 기반 ｃａｒ의 용도 | |
| JP2024023232A5 (cg-RX-API-DMAC7.html) | ||
| WO2019154391A1 (zh) | 嵌合抗原受体、表达该嵌合抗原受体的nkg2d car-nk细胞及其制备方法和应用 | |
| KR20170093248A (ko) | 탄산무수화효소 ix 특이적 키메라 항원 수용체 및 이의 사용 방법 | |
| KR20180021683A (ko) | 생체내 지속성 및 치료학적 활성 및 이의 증식을 위한 nkt-세포 서브세트 | |
| US20200078403A1 (en) | Use of Chimeric Antigen Receptor Modified Cells to Treat Autoimmune Disease | |
| WO2023133540A1 (en) | Il-12 affinity variants | |
| CN110724199A (zh) | Nkg2d car-t细胞及其制备和应用 | |
| WO2021068108A1 (zh) | Nkg2d car-t细胞及其制备和应用 | |
| CN114127287A (zh) | 乙酰胆碱受体嵌合自身抗体受体细胞的组合物和方法 | |
| CN112533629A (zh) | 结合使用il-10药剂与嵌合抗原受体细胞疗法的组合物和方法 | |
| Lo Presti et al. | Use of cord blood derived T-cells in cancer immunotherapy: milestones achieved and future perspectives | |
| JP7057975B2 (ja) | 殺細胞効果を有するキメラ抗原受容体遺伝子改変リンパ球 | |
| TWI881992B (zh) | Ｔ細胞受體及其使用方法 | |
| US20230295568A1 (en) | Chimeric antigen receptor gene-modified lymphocyte having cytocidal effect |